ArticleBMC pharmacology & toxicology2025
Integrative network toxicology, transcriptomic, and molecular docking approaches to elucidate the toxicity and mechanisms of bisphenol A in stroke.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBisphenol A (BPA), a widespread environmental endocrine disruptor, has raised concerns for its neurotoxic effects, yet its molecular role in stroke remains unclear.
methodsBPA target genes were retrieved from ChEMBL, DrugBank, and SwissTargetPrediction. Differentially expressed genes (DEGs) and key co-expression modules related to stroke were identified from the GSE16561 dataset using weighted gene co-expression network analysis (WGCNA). Core targets were determined by overlapping BPA targets, DEGs, and genes within significant WGCNA modules, followed by protein–protein interaction (PPI) network analysis. Functional enrichment was conducted using DAVID, and molecular docking assessed BPA’s binding affinity to the identified core targets.
resultsAnalysis of GSE16561 identified 1,801 DEGs. Intersection with BPA targets and WGCNA module genes yielded 22 candidate genes. PPI network topology analysis (MCC, closeness, degree) highlighted 10 core targets: NDUFB7, NDUFA11, NDUFB11, NDUFB8, NDUFS8, NDUFA12, NDUFS5, NDUFA8, NDUFV1, and NDUFA13. Functional enrichment revealed 12 significant Gene Ontology terms and 14 KEGG pathways. Molecular docking demonstrated stable binding of BPA to all 10 core targets, with NDUFA11 (− 7.7 kcal/mol) and NDUFV1 (− 7.4 kcal/mol) exhibiting the highest binding affinities.
conclusionThis study is the first to systematically elucidate the role of BPA exposure in stroke and its potential molecular mechanisms, providing important evidence for understanding the toxicological effects of BPA. In addition, it offers a theoretical basis for developing strategies to prevent and mitigate cerebrovascular injury associated with BPA exposure. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.